Lawmakers urge USPTO to curb IPR denials under Fintiv
21-09-2021
Intel backs Mylan's anti-Fintiv SCOTUS stance
16-09-2021
Mylan asks SCOTUS to end NHK-Fintiv rule
16-08-2021
FTC orders Mylan to divest two generics
09-09-2016
Bill Perry / Shutterstock.com
Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review (IPR) petitions that have been denied due to the NHK-Fintiv rule.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
NHK-Fintiv, Apple, Verizon, Comcast, Mylan Pharmaceuticals, inter partes review, US Supreme Court, US Court of Appeals for the Federal Circuit, patents
